Roberts C.Kean L.Archer D.Balkan C.Hsu L.L.2019-10-272019-10-2720050077-8923https://doi.org/10.1196/annals.1345.061https://hdl.handle.net/11454/22288Stable mixed chimeric stem cell transplantation in hemoglobinopathies exploits shorter erythroid survival in hemolytic anemias, providing normal donor red blood cells with a competitive survival advantage. This study examined the level of stable mixed chimerism necessary for complete hematological cure of the thalassemic phenotype, using a nonmyeloablative busulfan chemotherapeutic preparation. Thalassemic mice transplanted from congenic wild-type donors developed partial mixed chimerism. Hematologic cure required >80% donor red blood cells and only >13% donor white blood cells. Murine and human transplant results were compared with a math model for survival advantage of donor peripheral blood cells produced by steady-state chimeric marrow. © 2005 New York Academy of Sciences.en10.1196/annals.1345.061info:eu-repo/semantics/closedAccessBone marrow transplantChimerismHemolytic anemiaMathematical modelMoose modelNonmyeloablative transplantSickle cellThalassemiaMurine and math models for the level of stable mixed chimerism to cure ß-thalassemia by nonmyeloablative bone marrow transplantationConference Object105442342816339691N/A